Maxigen Biotech Inc. Integrity, passion and professionalism are not just promises to our customers, but also commitments we make to ourselves.

Similar documents
Biomaterials Line. MIS Corporation. All Rights Reserved.

Innovative Range of Regenerative Solutions

Versatile grafting Solutions

Your Partner in Healing

Wednesday 26 th November 2008 The ASX Company Announcements office: Chairman s AGM Address

More than bone regeneration. A total solution.

Adding a New Dimension to Osseointegration. Thinner. Faster. Stronger.

For personal use only. Investor Briefing. Bayswater, 1 st December 2016

Nano Interface Technology, Inc.

A WIDE RANGE OF REGENERATIVE SOLUTIONS

BEGO BIOMATERIALS When the result counts

Bioactive Glass Biphasic β-tcp & HA Granules Alkylene Oxide Polymer Carrier. MEDLINEUNITE Bioactive Bone Graft

THE ESSENTIALS IN BONE GRAFTING BRIDGING MEDICAL GAPS

Dental Bone Graft Market Research Report - Forecast to 2027

Bone augmentation with biomaterials

Cerasorb M DENTAL. O:\Zulassung\Cerasorb Dental Kanada 2013\Texte\Cerasorb M Dental final IFU docx

Guided Tissue and Bone Regeneration

Agreement to Acquire Spinal Kinetics, Inc. March 15, 2018

Better Diagnostics for Life

Company Presentation 2016

botiss dental bone & tissue regeneration biomaterials collacone max Innovative composite matrix socket preservation form-fitting resorbable composite

Letter to Shareholders SEMI-ANNUAL REPORT 2008

BioVin Collagen Membrane

PATIENT INFORMATION INFLAMED GUMS NOW WHAT? Gain of keratinized tissue

Graft Delivery Devices

Cell Therapy. Cytori Corporate Presentation January 2012

THE NEXT FRONTIER OF BONE REGENERATION

Regeneration Bone Grafting & Soft Tissue Management

Symbios Xenograft Granules Porcine Bone Graft Material

botiss biomaterials bone & tissue regeneration collacone max Innovative composite matrix socket preservation form-fitting resorbable composite

NanoMarkets Report. Worldwide Medical Ceramics Markets Nano-655

Bone augmentation with maxgraft

THE NEXT FRONTIER OF BONE REGENERATION. where Technology meets Nature

THE NEXT FRONTIER OF BONE REGENERATION. where Technology meets Nature

BIOMATERIALS. What is a Biomaterial? Attention! Info on Term Projects. Anything in contact with human body?

Consumer Health Care V5.0_2013

Introducing BSI. BSI Medical Device Regulatory Update Galway, Ireland. Dr. Michael Weissig EMEA Vice President Healthcare 26 June, 2015

The Original remains unique.

CHAPTER 1. Clinical Problems Requiring Implants for Solution: Defining the Problem

Boehringer Ingelheim Biopharmaceuticals in China. Your Reliable Contract Manufacturing Solution Provider

The more question you ask the more different answers you will get

A GLOBAL LEADER IN PERSONALIZED NUTRITION

Regeneration Bone Grafting & Soft Tissue Management

B U I L D S T R O N G B O N E F A S T

To be the partner of choice Straumann

PATIENT INFORMATION WHEN IMPLANTS BECOME VISIBLE. Minor Bone Augmentation

Business Update & Financial Results for Q1 2018

China Cranio Maxillofacial Fixation (CMF) Market Outlook to 2020

HeartSciences MyoVista High Sensitivity ECG Technology LAUNCH Key Messages and Q&A Updated: August 17, 2017

Index. Note: Page numbers of article titles are in boldface type.

Straumann reports 4% growth in local currencies (l.c.) in the first nine months of 2010

F. W. Taylor. DIACLON is the best partner for companies which commit to providing high quality.

Universal Biosensors, Inc.

Innovative Tissue Regeneration Technologies. Bonus BioGroup Investors Presentation

PATIENT INFORMATION EXPOSED TOOTH ROOTS NOW WHAT? Recession coverage

GmbH DENTAL IMPLANT SYSTEMS PRODUCT CATALOG

chronos Bone Void Filler. Beta-Tricalcium Phosphate ( β-tcp) bone graft substitute.

Location of HENGRUI. The Headquarters: No.7 Kunlunshan Road, Economic & Technological Development Zone Lianyungang, Jiangsu, China

Regeneration Bone Grafting & Soft Tissue Management

For personal use only

In the last decade of the 20 th century, special emphasis was put on an emerging field of science: Tissue engineering,which combines the state of the

For personal use only

Worldwide Nanotechnology Dental Implants-- Markets Reach $8.1 By 2015

experts in bone regeneration Spine Surgery Product Line When Innovation Meets Performance

Product Information. MIS Corporation. All Rights Reserved.

Sub-components in Nicotine cessation products?

Professional Wound Management

Table of Contents: JULY TH EDITION

38 COUNTRIES. Company Overview. Over 290,000 cases Implanted Worldwide. In-house Manufacturing. International Distribution.

Shareholder Presentation Annual Meeting 2018

Graftys. Cross-selling. Indications. Comparison. Basic Science. Graftys 415 rue Claude Nicolas Ledoux Aix en Provence Cedex 4

Inion BioRestore. Bone Graft Substitute. Product Overview

GLOBAL NEUROSTIMULATION MARKET

BONE GRAFTING. Product Catalog

Bacterin International Incorporated Mr. Howard L. Schrayer 600 Cruiser Lane Belgrade, Montana August 18, 2015

REASONS TO USE R.T.R.

Better Diagnostics for Life

easy-graft TM CRYSTAL

Transformational Products in Soft Tissue Regeneration and Cartilage Repair

CELLPLEX TCP SYNTHETIC CANCELLOUS BONE

ADVANCED BONE GRAFT SYSTEM OVERVIEW

ONCOLOGY: WHEN EXPERTISE, EXPERIENCE AND DATA MATTER. KANTAR HEALTH ONCOLOGY SOLUTIONS: FOCUSED I DEDICATED I HERITAGE

Investor Presentation Post-Interim Results Update. September 2011

Medical Device VSP Design & Manufacturing. Virtual Surgical Planning

DRIVING THE FUTURE. About HOSPITAL INNOVATIONS. Strong commitment to healthcare innovation

China Orthopedics Implants Medical Devices Market Brief

SCIENTIFIC RESEARCH TECHNOLOGY QUALITY RELIABILITY FOR YOUR PATIENTS, WITHIN EVERYONE S REACH.

BIOACTIVE BASICS. Bioactive materials elicit a controlled action and reaction in the physiological environment.

SAMPLE. South Korea Orthopedic Procedures Outlook to Reference Code: GDMEMC0008PDB. Publication Date: March 2014

POWER TO RESTORE WITHOUT LEAVING A TRACE. The only remaining evidence of the trauma

STRADEFY STRATEGIC DERMATOLOGIC ENGINEERING FROM YALE

Pattern of bone resorption after extraction

AttraX. Portfolio. Surface Drives Performance

Prident SmartSourcing Services: Outsourcing for Today s Cost-Effective Dental Lab

Russia Cardiac Assist Devices Market Outlook to 2021

THE NATU R R E A G L E N P E R R O A M TI O O T N ER OF

The dental market. Facts, trends and dynamics.

概美科技. GuideMia Technologies, LLC Sept

Resorbable bilayer synthetic membrane Biomimetic tissue-engineered matrix for GBR and GTR

For personal use only

Transcription:

Maxigen Biotech Inc. Integrity, passion and professionalism are not just promises to our customers, but also commitments we make to ourselves. 1

Company profile Company name Maxigen Biotech Inc. (MBI) (Stock code:1783) Established December, 1998 Cap. G.M. Core competency NTD 710 million (USD 23 million) Edward Chang Ph.D Developing, manufacturing, and marketing of biomedical and cosmeceutical skincare products Major product Major Shareholders Medical devices for Orthopedics, Dental, Ophthalmology, and Wound Dressing. Cosmeceutical skincare GIH Group, Mega International Commercial Bank, First Financial Holding, NuVasive Inc.(Nasdaq:NUVA) 2

Milestones 1999 2002 2006 2007 2009 2010 2011 Established R&D center at Yang Ming university. GIH Group invested in MBI. Established Taipei medical devices facility and Tainan skincare facility. Biomedical Products Formagraft, Foramic, ArtiAid, and ViscAid received market approval. Enlisted US NASDAQ listed company, NuVasive, as investor and strategic partner. Taipei biomedical facility passed FDA inspection with no observations. Tainan skin care facility received Taiwan GMP certificate. Biomedical Products - Foramic, ArtiAid and ViscAid received CE mark. Biomedical Product - SurgiAid received FDA approval. 2012 2013 Entered into a technical development agreement with Exactech.(Nasdaq:EXAC) Initiated Public Offering.

Milestones 2007 NuVasive,as investor and strategic partner 2009 passed FDA inspection with no observations. 2009 Won Commendable in the Taiwan Healthcare Industry Innovation and Excellence Awards. 2012 Partnered with Exectech 2013 Contracted with Shanghai Fosun Pharma 2013 IPO 2013 IPO 4

MBI facility location

Medical Devices division 6

Core Technology The core technology of Maxigen medical device was using natural biomaterials such as Collagen, Hyaluronic Acid, Bioceramic to develop the implanted medical device External Artificial Scaffold was used to mimic the environment of ECM Defect Implanted Artificial Scaffold can provide space for cell migration and attachment The defect tissue was then repaired and regenerated. And, Artificial Scaffold was degraded by the enzyme of body

Applications Orthopedics Bone Cement Bone Void Filler Dentistry Bone Graft GTR Wound/Skin Orthopedics Dressing Dermal Filler Ophthalmology Viscosurgical device Gastroenterological Anti-adhesive Dental Gastroenterology Ophthalmology 8

Technology platform Fundamental materials Technology platform Technology protection Application Market Scale(B) Collagen extraction Patent Orthopedics Dental 1.0 High polymer Collagen HA Collagenceramic technology Patent Orthopaedy Skincare 2.0 Ceramic materials Hydroxyapatite β-tricalcium phosphate Absorbable calcium phosphate ceramic technique Cross linked hyaluronic acid Patent Know How Orthopedics Dental Gastroenterology Ophthalmology Orthopedics Dental 2.5 4.5 9

Collagen product line HealiAid /SurgiAid Collagen wound dressing membrane (Taiwan USA Singapore) FormaAid Guided Tissue Regeneration (GTR) membrane in periodontal treatments (Taiwan, Singapore) 10

11 Ceramic bone graft product line Foramic Ceramic bone graft (Taiwan EU Singapore) MaxiBone Calcium Phosphate Ceramic(Taiwan) PRP Macropores (65%) Micropores (35%) Formasetin Bone Void Filler (Taiwan) Completely bone filling in voids or gaps

Collagen/Ceramic materials product line FormaGraft Collagen bone graft substitute (Taiwan, USA) GingivAid Collagen bone graft substitute for dental and orthopedics (Taiwan Singapore) Spinal Fusion

Hyaluronic Acid product line ViscAid /PreviscAid Ophthalmic viscosurgical device (Taiwan, China, EU) ArtiAid /ArtiAid Plus Intra-articular Injection (Taiwan, EU) Cross linking Formaderm Dermal Filler Injection (Taiwan, EU) Before implantation Strengthen enzyme resistance Extending degradation rate Highly structural support After implantation 13

Biomedical materials product list Category Product License Collagen Hyaluronic Acid Ceramic materials SurgiAid Collagen Wound Dressing HealiAid Collagen Wound Dressing FormaAid Collagen Membrane Formagraft Collagen Bone Graft GingivAid Collagen Bone Graft GingivAid Collagen Dental Bone Graft ViscAid Ophthalmic Viscoelastic ArtiAid Intra-articular Injection ArtiAid Plus Intra-articular Injection Formaderm Dermal Filler Injection Formacare External Aesthetic Restoration Foramic Bone Graft Substitute MaxiBone Calcium Phosphate Ceramic Formasetin Bone Void Filler TFDA USFDA, TFDA, HSA TFDA, HSA USFDA, TFDA TFDA TFDA, HSA CE, CFDA, TFDA CE, TFDA CE, TFDA CE, TFDA TFDA CE, TFDA, HSA TFDA TFDA

MBI s Product Pipeline Product Line In Market (Current) In Process (2014~2016) In R&D (2015~2017) Hyaluronic acid crosslinking Formaderm Dermal Filler ArtiAid Intralcular Injection (5- dose) ArtiAid Plus (3-dose) ViscAid Ophthalmic Viscoelastic Formacare Formaderm Series Products (4 products) ArtiBest Intra-articular Injection (1-dose) MaxiGel Anti-adhesive Gel Collagen/ bioceramic FormaAid Collagen Membrane FormaGraft Collagen Bone Matrix GingivAid Collagen Bone Graft MaxiGuide GTR Membrane MaxiCure Bone Graft MaxiCage Resorbable Cage Resorbable bioceramic Formic Bone Substitute MaxiBone Calcium Phosphate Ceramic Formasetin Injectable Bone Filler MaxCement High Performance Cement MaxiSetin Antibiotic Filler Currently, 11 products were commercialized with 18 licenses 13 additional products expected to be commercialized within the next 3 to 5 years

Products launched in Europe Launched Products ViscAid Ophthalmic Viscoelastic ArtiAid Intra-articular Injection ArtiAid Plus Intra-articular Injection Foramic Bone Graft Substitute Products under Registration SurgiAid Collagen Wound Dressing FormaAid Collagen Membrane GingivAid Collagen Bone Graft

Passed US FDA Inspection with No Observation

GMP and ISO 13485 Certifications

MBI Product advantages Core techniques under patent protection. Complied with international biomedical materials standards and regulations. Great effects of therapy and easy on surgical operation. Equipped with the superior quality as worldwide big name companies and competitive prices. Comprehensive product lines and specifications, offering effective solutions. Providing customized product development services.

Maxigen Biotech Inc. Thank you for your attention